The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
about
Decreasing racial disparity with the combination of ledipasvir-sofosbuvir for the treatment of chronic hepatitis CTreatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.Genomic variants link to hepatitis C racial disparities.Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population.Race or genetic makeup for hepatitis C virus treatment decisions?The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients.Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort studyRecovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir
P2860
Q37714088-7B2E5F1A-A3DA-4877-885E-417D90852852Q38693657-85102B63-8BE0-412C-B591-1F7CA99BD998Q40050150-1EC95D41-9095-4955-9184-66F62F3393C9Q40171277-1017911D-EFE8-412F-B3C9-EDF5DC7C7DD5Q41708713-02FB71D5-96CD-49A1-A39F-E0781D794BE0Q41923073-42AD4535-D221-4E40-9FCE-3C5B292AEBC2Q45330951-BE1BC741-9E70-4EAE-A983-1B53FBE1CDA1Q47550695-CEE96CFA-DC4B-4413-9A12-A517DCE5C3F5Q52661697-E746642A-8795-488F-8EBC-77AD0FCDED0BQ54256586-18697C39-73A8-4306-B7D7-028591BEC9E7Q55259186-1141A021-9498-4D51-9C82-485F4A6F3CFFQ57841241-88FBEB3C-1206-4489-92BF-E7EF6A464E34Q58602166-09EA66A4-8245-4482-AA5A-AB31ACE6153D
P2860
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The association between race/e ...... r hepatitis C virus infection.
@en
The association between race/e ...... r hepatitis C virus infection.
@nl
type
label
The association between race/e ...... r hepatitis C virus infection.
@en
The association between race/e ...... r hepatitis C virus infection.
@nl
prefLabel
The association between race/e ...... r hepatitis C virus infection.
@en
The association between race/e ...... r hepatitis C virus infection.
@nl
P2093
P2860
P356
P1433
P1476
The association between race/e ...... r hepatitis C virus infection.
@en
P2093
George N Ioannou
Kristin Berry
Pamela K Green
P2860
P304
P356
10.1002/HEP.28901
P407
P577
2016-10-24T00:00:00Z